B-ALL MRD Flow Panel
Also known as: B-ALL Minimal Residual Disease Panel
Use
The B-ALL MRD Flow Panel utilizes flow cytometry to detect minimal residual disease (MRD) in patients with B-cell acute lymphoblastic leukemia (B-ALL). It is designed to identify specific cell markers that are significant in understanding the extent of disease and assessing treatment response.
Special Instructions
Available as a global test only. New York clients have specific submission requirements; please provide the date and time of collection. An additional CBC report is necessary to confirm sample viability.
Limitations
Flow cytometry detection of MRD is limited to the markers included in the panel. Sample integrity must be maintained by adhering to the storage and transportation guidelines, which require refrigeration and timely submission within specified hours of collection.
New York Approved
Methodology
Cell-based / Cytometry (Flow Cytometry)
Biomarkers
Result Turnaround Time
1 day
Related Documents
For more information, please review the documents below
Specimen
Bone Marrow
Volume
2-3 mL
Minimum Volume
Not provided
Container
EDTA or sodium heparin
Patient Preparation
Please provide recent CBC report.
Storage Instructions
Refrigerate specimen. Use cold pack for transport, ensuring it is not in direct contact with specimen.
Causes for Rejection
Lithium heparin or ACD (pale yellow/no gel separator) is not acceptable.